UCB and Biogen’s drug dapirolizumab pegol has met the primary endpoint of improvement in disease activity in lupus patients.

Dapirolizumab pegol is an investigational Fc-free polyethylene glycol-conjugated antigen-binding fragment that inhibits CD40 ligand signaling.

UCB and Biogen have announced positive Phase III clinical trial results for PHOENYCS GO study, evaluating dapirolizumab pegol, a new treatment for moderate-to-severe systemic lupus erythematosus (SLE) ...

CD40–CD40L signaling may regulate both the initiation and effector phases of B- and T-cell responses, as well as transmigration of activated cells to target tissues. Direct therapy against this ...

It is difficult to predict with a sufficient degree of accuracy using the techniques currently available whether a biopharmaceutical will be immunogenic when tested in humans and if so, to what ...

Tonix Pharmaceuticals (NASDAQ: TNXP) , a fully integrated biopharmaceutical company with marketed products and a pipeline of development candidates ...

Objective To identify differentially expressed genes in temporal artery biopsies (TABs) from patients with giant cell arteritis (GCA) with different histological patterns of inflammation: transmural ...

Both circulating and mucosal platelets express activation markers such as P-selectin and CD40L, and are able activate HIMECs in a CD40-dependent manner, resulting in increased surface expression of ...

Tonix's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting ...

这些药物包括：优化肿瘤抗原释放和呈递的药物（放疗，化疗，癌症疫苗，溶瘤病毒），激活共刺激分子以改善抗原呈递细胞（APCs）活性（靶向ICOS，ICOSL，OX40，CD40和CD40L的受体激动剂），以及靶向先天免疫的药物，例如：模式识别受体（PRRs）、细胞因子、自然 ...